Ventyx Biosciences (VTYX) Competitors $1.87 -0.10 (-5.08%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VTYX vs. SLRN, MREO, CRVS, LRMR, RGNX, ALMS, ALEC, AURA, VERV, and QTTBShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Acelyrin (SLRN), Mereo BioPharma Group (MREO), Corvus Pharmaceuticals (CRVS), Larimar Therapeutics (LRMR), REGENXBIO (RGNX), Alumis (ALMS), Alector (ALEC), Aura Biosciences (AURA), Verve Therapeutics (VERV), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Acelyrin Mereo BioPharma Group Corvus Pharmaceuticals Larimar Therapeutics REGENXBIO Alumis Alector Aura Biosciences Verve Therapeutics Q32 Bio Acelyrin (NASDAQ:SLRN) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Do analysts rate SLRN or VTYX? Acelyrin currently has a consensus price target of $11.50, indicating a potential upside of 145.20%. Ventyx Biosciences has a consensus price target of $10.00, indicating a potential upside of 434.76%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community prefer SLRN or VTYX? Ventyx Biosciences received 16 more outperform votes than Acelyrin when rated by MarketBeat users. However, 60.00% of users gave Acelyrin an outperform vote while only 47.69% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformAcelyrinOutperform Votes1560.00% Underperform Votes1040.00% Ventyx BiosciencesOutperform Votes3147.69% Underperform Votes3452.31% Do insiders and institutionals hold more shares of SLRN or VTYX? 87.3% of Acelyrin shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 13.6% of Acelyrin shares are held by insiders. Comparatively, 18.2% of Ventyx Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, SLRN or VTYX? Acelyrin is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.46-1.91Ventyx BiosciencesN/AN/A-$192.96M-$2.36-0.79 Which has more volatility & risk, SLRN or VTYX? Acelyrin has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Does the media prefer SLRN or VTYX? In the previous week, Acelyrin had 3 more articles in the media than Ventyx Biosciences. MarketBeat recorded 10 mentions for Acelyrin and 7 mentions for Ventyx Biosciences. Acelyrin's average media sentiment score of 1.04 beat Ventyx Biosciences' score of 0.08 indicating that Acelyrin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acelyrin 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ventyx Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SLRN or VTYX more profitable? Acelyrin's return on equity of -44.12% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Ventyx Biosciences N/A -54.94%-50.01% SummaryVentyx Biosciences beats Acelyrin on 9 of the 15 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.23M$6.48B$5.12B$8.72BDividend YieldN/A8.13%5.18%4.07%P/E Ratio-0.795.6972.8114.16Price / SalesN/A349.551,250.2081.71Price / CashN/A53.3440.7036.03Price / Book0.479.606.455.94Net Income-$192.96M$154.43M$119.73M$225.73M7 Day Performance-15.00%-9.46%-5.13%-1.34%1 Month Performance-23.67%-7.27%-2.71%1.15%1 Year Performance-24.29%28.13%31.08%24.02% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.6067 of 5 stars$1.87-5.1%$10.00+434.8%-20.8%$132.23MN/A-0.7973SLRNAcelyrin3.4174 of 5 stars$6.06+2.7%N/A-46.9%$604.85MN/A-2.13135Analyst ForecastAnalyst RevisionNews CoveragePositive NewsMREOMereo BioPharma Group3.4308 of 5 stars$4.28+0.5%N/A+71.4%$600.30M$1M0.0040Analyst ForecastNews CoverageCRVSCorvus Pharmaceuticals2.5198 of 5 stars$9.56+1.2%N/A+493.5%$597.98MN/A-21.2430Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageLRMRLarimar Therapeutics3.6953 of 5 stars$9.29+4.1%N/A+116.5%$592.77MN/A-8.0830Short Interest ↓Positive NewsRGNXREGENXBIO4.377 of 5 stars$11.56+3.6%N/A-48.9%$572.68M$90.24M-2.30344Analyst ForecastNews CoverageGap UpALMSAlumisN/A$11.84-1.5%N/AN/A$567.56MN/A0.00N/AAnalyst ForecastAnalyst RevisionNews CoverageALECAlector4.3865 of 5 stars$6.06+5.4%N/A+3.2%$563.11M$97.06M-3.56270News CoverageAURAAura Biosciences3.5549 of 5 stars$11.14+2.4%N/A+17.3%$552.66MN/A-6.2250Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageVERVVerve Therapeutics2.2891 of 5 stars$6.42+1.7%N/A-56.4%$543.54M$24.40M-2.61110Analyst RevisionHigh Trading VolumeQTTBQ32 Bio2.0011 of 5 stars$45.01-0.6%N/AN/A$542.82M$1.16M-3.1639 Related Companies and Tools Related Companies Acelyrin Competitors Mereo BioPharma Group Competitors Corvus Pharmaceuticals Competitors Larimar Therapeutics Competitors REGENXBIO Competitors Alumis Competitors Alector Competitors Aura Biosciences Competitors Verve Therapeutics Competitors Q32 Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTYX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTYX Stock Alerts